Arrowhead Pharmaceuticals Inc
ARWR16.760USD
-2.090-11.09%
Close 07/18, 16:00（ET）Quotes delayed by 15 min
2.31BMarket Cap
LossP/E TTM
More Details of Arrowhead Pharmaceuticals Inc Company
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.
Company Info
Ticker SymbolARWR
Company nameArrowhead Pharmaceuticals Inc
IPO dateDec 14, 1993
Founded at2001
CEODr. Christopher Richard (Chris) Anzalone, Ph.D.
Number of employees609
Security typeOrdinary Share
Fiscal year-endDec 14
Address177 E Colorado Blvd
CityPASADENA
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code91105
Phone16266964702
Websitehttps://arrowheadpharma.com/
Ticker SymbolARWR
IPO dateDec 14, 1993
Founded at2001
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
3.92M
-3.47%
Mr. Patrick C. O'Brien, J.D.
Mr. Patrick C. O'Brien, J.D.
Chief Operating Officer, General Counsel, Company Secretary
Chief Operating Officer, General Counsel, Company Secretary
527.20K
+13.53%
Dr. Michael S. (Mike) Perry, Ph.D.
Dr. Michael S. (Mike) Perry, Ph.D.
Independent Director
Independent Director
131.49K
--
Dr. Mauro Ferrari, Ph.D.
Dr. Mauro Ferrari, Ph.D.
Independent Director
Independent Director
77.51K
-2.39%
Dr. Hongbo B. Lu, Ph.D.
Dr. Hongbo B. Lu, Ph.D.
Independent Director
Independent Director
47.16K
-6.45%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
38.40K
--
Ms. Victoria (Vicki) Vakiener
Ms. Victoria (Vicki) Vakiener
Independent Director
Independent Director
37.94K
+0.01%
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Independent Director
Independent Director
35.78K
-2.60%
Mr. Daniel Apel
Mr. Daniel Apel
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Vincent Anzalone
Mr. Vincent Anzalone
Investor Relations
Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
3.92M
-3.47%
Mr. Patrick C. O'Brien, J.D.
Mr. Patrick C. O'Brien, J.D.
Chief Operating Officer, General Counsel, Company Secretary
Chief Operating Officer, General Counsel, Company Secretary
527.20K
+13.53%
Dr. Michael S. (Mike) Perry, Ph.D.
Dr. Michael S. (Mike) Perry, Ph.D.
Independent Director
Independent Director
131.49K
--
Dr. Mauro Ferrari, Ph.D.
Dr. Mauro Ferrari, Ph.D.
Independent Director
Independent Director
77.51K
-2.39%
Dr. Hongbo B. Lu, Ph.D.
Dr. Hongbo B. Lu, Ph.D.
Independent Director
Independent Director
47.16K
-6.45%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
38.40K
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 23
Updated: Fri, May 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.17%
The Vanguard Group, Inc.
9.54%
Sarepta Therapeutics Inc
8.64%
Avoro Capital Advisors LLC
8.05%
State Street Global Advisors (US)
5.07%
Other
55.54%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.17%
The Vanguard Group, Inc.
9.54%
Sarepta Therapeutics Inc
8.64%
Avoro Capital Advisors LLC
8.05%
State Street Global Advisors (US)
5.07%
Other
55.54%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
32.28%
Investment Advisor
30.49%
Corporation
8.64%
Hedge Fund
7.81%
Individual Investor
4.38%
Research Firm
3.19%
Sovereign Wealth Fund
1.49%
Pension Fund
0.97%
Bank and Trust
0.87%
Other
9.89%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
575
124.62M
90.24%
+6.96M
2025Q1
603
125.23M
90.71%
+6.54M
2024Q4
609
108.09M
85.81%
-8.58M
2024Q3
605
106.83M
85.95%
-7.44M
2024Q2
608
107.20M
86.35%
-5.57M
2024Q1
621
105.82M
85.63%
+13.72M
2023Q4
625
87.51M
81.46%
-1.31M
2023Q3
624
83.79M
78.09%
-822.40K
2023Q2
641
80.82M
75.59%
-4.71M
2023Q1
648
81.64M
75.46%
-182.63K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
18.18M
13.17%
+3.66M
+25.22%
Mar 31, 2025
The Vanguard Group, Inc.
13.18M
9.54%
+1.02M
+8.37%
Mar 31, 2025
Sarepta Therapeutics Inc
11.93M
8.64%
+11.93M
--
Feb 07, 2025
Avoro Capital Advisors LLC
11.11M
8.05%
--
--
Mar 31, 2025
State Street Global Advisors (US)
7.00M
5.07%
+983.02K
+16.34%
Mar 31, 2025
Slate Path Capital LP
5.23M
3.79%
--
--
Mar 31, 2025
Anzalone (Christopher Richard)
3.92M
2.84%
-141.12K
-3.47%
Apr 11, 2025
Fidelity Management & Research Company LLC
3.32M
2.4%
-1.74M
-34.40%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.95M
2.14%
-4.63K
-0.16%
Mar 31, 2025
UBS Asset Management (Switzerland)
2.95M
2.13%
+1.18M
+67.22%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
Global X Genomics & Biotechnology ETF
2.56%
ROBO Global Healthcare Technology & Innovation ETF
1.79%
Invesco S&P SmallCap Health Care ETF
1.44%
Tema Heart & Health ETF
1.07%
Virtus LifeSci Biotech Clinical Trials ETF
0.91%
SPDR S&P Biotech ETF
0.59%
Invesco NASDAQ Future Gen 200 ETF
0.52%
Direxion Daily S&P Biotech Bull 3X Shares
0.45%
WisdomTree BioRevolution Fund
0.44%
Amplify Etho Climate Leadership U.S. ETF
0.39%
View more
Global X Genomics & Biotechnology ETF
Proportion2.56%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.79%
Invesco S&P SmallCap Health Care ETF
Proportion1.44%
Tema Heart & Health ETF
Proportion1.07%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.91%
SPDR S&P Biotech ETF
Proportion0.59%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.52%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.45%
WisdomTree BioRevolution Fund
Proportion0.44%
Amplify Etho Climate Leadership U.S. ETF
Proportion0.39%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
